Designing dendrimers for ocular drug delivery
Authors:
- François MalecazeFMFrançois Malecaze
- Cédric-Olivier TurrinCTCédric-Olivier Turrin
- Vincent SolerVSVincent Soler
- Carine DuhayonCDCarine Duhayon
- Pierre-Paul ElenaPEPierre-Paul Elena
- Jean-Pierre MajoralJMJean-Pierre Majoral
- Anne-Marie CaminadeAnne-Marie Caminade
- 1 January 2010
- journal article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 45 (1) , 326-334
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Interactions between dendrimers and heparin and their implications for the anti-prion activity of dendrimersNew Journal of Chemistry, 2009
- Polycationic phosphorus dendrimers: synthesis, characterization, study of cytotoxicity, complexation of DNA, and transfection experimentsNew Journal of Chemistry, 2008
- Influence of phosphorus dendrimers on the aggregation of the prion peptide PrP 185–208Biochemical and Biophysical Research Communications, 2007
- EPR Study of the Interactions between Dendrimers and Peptides Involved in Alzheimer's and Prion DiseasesMacromolecular Bioscience, 2007
- Fixed-combination and emerging glaucoma therapiesExpert Opinion on Emerging Drugs, 2007
- Multiplication of Human Natural Killer Cells by Nanosized Phosphonate‐Capped DendrimersAngewandte Chemie International Edition, 2007
- Dendrimers as drug delivery vehicles: non‐covalent interactions of bioactive compounds with dendrimersPolymer International, 2007
- Ocular CarteololDrugs & Aging, 2007
- Novel Water‐Soluble Carbosilane Dendrimers: Synthesis and BiocompatibilityEuropean Journal of Inorganic Chemistry, 2006
- Ophthalmic drug discoveryNature Reviews Drug Discovery, 2003